BioCentury | Jul 9, 2020
Finance

Forbion catering to abundance of maturing European biotechs with new growth fund

Forbion’s launch of a new late-stage and crossover fund reflects the growing need for capital among maturing European biotechs, including those that are past the proof-of-concept stage and are seeking liquidity. Over the past few...
BioCentury | Jul 1, 2020
Emerging Company Profile

With potential for re-dosing, Carmine’s gene therapy tech attracts Takeda as partner

Carmine is developing red blood cell-based vesicles to deliver gene therapies, offering immunogenicity and manufacturing advantages over viral vector systems. The platform, which offers the potential for re-dosable gene therapies, led Takeda to become Carmine’s...
BioCentury | Jun 18, 2020
Emerging Company Profile

Lassen emerges from Frazier with over $31M and a mAb for fibrosis and cancer

After incubating in Frazier for a year and half, Lassen emerged from stealth Wednesday with a preclinical program targeting the IL-11 receptor that could be applied to both fibrosis and cancer and enough funds to...
BioCentury | May 16, 2020
Management Tracks

Management Tracks: Evox, Phoenix Tissue Repair, Artax, Nucleix, IsoPlexis, Centogene, Immunicum, CohBar and CorMedix

Evox Therapeutics Ltd. said Paul Carter will succeed Edwin Moses as non-executive chairman. Carter was EVP, chief commercial officer of Gilead Sciences Inc. (NASDAQ:GILD). The exosome therapeutics company partnered with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502;...
BioCentury | Apr 18, 2020
Finance

April 17 Quick Takes: Mabworks’ $160M series C; plus RDMD, PIC, SIRS, Atomo and Lantern

Beijing antibody play Mabworks raises $160M  Mabworks Biotech Co. Ltd. raised RMB1.1 billion ($160 million) in series C1 and C2 rounds to support development and commercialization of its antibody pipeline for various cancers, autoimmune, metabolic...
BioCentury | Feb 8, 2020
Finance

Forbion leads Azafaros’ €25M series A, with rare disease vet as chair

With a €25 million ($27.7 million) series A commitment, an investor syndicate led by Forbion believes Dutch start-up Azafaros can develop a dual inhibitor of glycometabolic processes to treat lysosomal storage disorders, particularly those with...
BC Extra | Jan 25, 2020
Company News

Management tracks: Galapagos promotes Manto to CCO; plus Guardant, Horizon, Acceleron, Lilly, Krystal, Kura and more

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) promoted Michele Manto to chief commercial officer from SVP, commercial operations. Before joining the inflammation and fibrosis company in 2017, he was general manager, global marketing rheumatology at AbbVie Inc. (NYSE:ABBV)....
BioCentury | Dec 19, 2019
Finance

Truffle’s recipe for company creation

Paris-based Truffle Capital has closed its €250 million ($277.9 million) BioMedTech fund to create new drug and medtech companies and nurture them through at least Phase II testing. The fund will channel around 30% of...
BC Innovations | Dec 11, 2019
Product Development

The writing has been on the wall for Sanofi’s diabetes, CV business for years

One hundred days after taking the helm as CEO, Paul Hudson has outlined a plan to get Sanofi to 30% margins by 2022 that hinges largely on the success of Dupixent and five other priority...
BioCentury | Nov 23, 2019
Product Development

Sanofi adds in home-grown trispecific antibody technology to grow oncology franchise

Promising preclinical data from a trispecific mAb platform developed by Sanofi could provide a new growth platform for its cancer pipeline, as the pharma seeks to wean off its reliance on Regeneron. Sanofi (Euronext:SAN; NYSE:SNY)...
Items per page:
1 - 10 of 3588
BioCentury | Jul 9, 2020
Finance

Forbion catering to abundance of maturing European biotechs with new growth fund

Forbion’s launch of a new late-stage and crossover fund reflects the growing need for capital among maturing European biotechs, including those that are past the proof-of-concept stage and are seeking liquidity. Over the past few...
BioCentury | Jul 1, 2020
Emerging Company Profile

With potential for re-dosing, Carmine’s gene therapy tech attracts Takeda as partner

Carmine is developing red blood cell-based vesicles to deliver gene therapies, offering immunogenicity and manufacturing advantages over viral vector systems. The platform, which offers the potential for re-dosable gene therapies, led Takeda to become Carmine’s...
BioCentury | Jun 18, 2020
Emerging Company Profile

Lassen emerges from Frazier with over $31M and a mAb for fibrosis and cancer

After incubating in Frazier for a year and half, Lassen emerged from stealth Wednesday with a preclinical program targeting the IL-11 receptor that could be applied to both fibrosis and cancer and enough funds to...
BioCentury | May 16, 2020
Management Tracks

Management Tracks: Evox, Phoenix Tissue Repair, Artax, Nucleix, IsoPlexis, Centogene, Immunicum, CohBar and CorMedix

Evox Therapeutics Ltd. said Paul Carter will succeed Edwin Moses as non-executive chairman. Carter was EVP, chief commercial officer of Gilead Sciences Inc. (NASDAQ:GILD). The exosome therapeutics company partnered with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502;...
BioCentury | Apr 18, 2020
Finance

April 17 Quick Takes: Mabworks’ $160M series C; plus RDMD, PIC, SIRS, Atomo and Lantern

Beijing antibody play Mabworks raises $160M  Mabworks Biotech Co. Ltd. raised RMB1.1 billion ($160 million) in series C1 and C2 rounds to support development and commercialization of its antibody pipeline for various cancers, autoimmune, metabolic...
BioCentury | Feb 8, 2020
Finance

Forbion leads Azafaros’ €25M series A, with rare disease vet as chair

With a €25 million ($27.7 million) series A commitment, an investor syndicate led by Forbion believes Dutch start-up Azafaros can develop a dual inhibitor of glycometabolic processes to treat lysosomal storage disorders, particularly those with...
BC Extra | Jan 25, 2020
Company News

Management tracks: Galapagos promotes Manto to CCO; plus Guardant, Horizon, Acceleron, Lilly, Krystal, Kura and more

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) promoted Michele Manto to chief commercial officer from SVP, commercial operations. Before joining the inflammation and fibrosis company in 2017, he was general manager, global marketing rheumatology at AbbVie Inc. (NYSE:ABBV)....
BioCentury | Dec 19, 2019
Finance

Truffle’s recipe for company creation

Paris-based Truffle Capital has closed its €250 million ($277.9 million) BioMedTech fund to create new drug and medtech companies and nurture them through at least Phase II testing. The fund will channel around 30% of...
BC Innovations | Dec 11, 2019
Product Development

The writing has been on the wall for Sanofi’s diabetes, CV business for years

One hundred days after taking the helm as CEO, Paul Hudson has outlined a plan to get Sanofi to 30% margins by 2022 that hinges largely on the success of Dupixent and five other priority...
BioCentury | Nov 23, 2019
Product Development

Sanofi adds in home-grown trispecific antibody technology to grow oncology franchise

Promising preclinical data from a trispecific mAb platform developed by Sanofi could provide a new growth platform for its cancer pipeline, as the pharma seeks to wean off its reliance on Regeneron. Sanofi (Euronext:SAN; NYSE:SNY)...
Items per page:
1 - 10 of 3588